Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
Travere Therapeutics (TVTX) Stock Price & Analysis
321 Followers
TVTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.12 - $17.96
Previous Close$7.27
Volume742.10K
Average Volume (3M)1.20M
Market Cap
$553.46M
Enterprise Value$391.39M
Total Cash (Recent Filing)$566.85M
Total Debt (Recent Filing)$404.78M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 01, 2024EPS Estimate
-$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.06
Shares Outstanding76,129,018
10 Day Avg. Volume957,257
30 Day Avg. Volume1,195,122
Standard Deviation0.17
R-Squared0.06
Alpha-0.00985
Financial Highlights & Ratios
Price to Book (P/B)5.75
Price to Sales (P/S)11.95
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit2.93
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$14.56Price Target Upside98.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Travere Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's solid financial position, with a runway into 2028, underscores its ability to sustain operations and invest in growth.
Market ExpansionWith the potential full FDA approval and less restrictive label, Filspari's addressable market could see significant expansion.
Regulatory MilestonesFilspari's strong impact on proteinuria and potential use in earlier treatment is well-supported by positive feedback from key opinion leaders in nephrology.
Bears Say
Earnings RevisionThe company's revised forecast suggests a larger loss per share than previously anticipated due to significant research and development costs.
Operational RisksThe company faces substantial risks including the possibility of clinical trial failures and a tough competitive landscape, which could adversely affect its financial stability and market position.
Regulatory ChallengesThe FDA's requirement for more comprehensive data may delay the company's ability to bring its key drug to market, potentially impacting future revenues.
---
Ownership Overview
7.98% Insiders
26.41% Mutual Funds
62.71% Other Institutional Investors
2.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $5.12 and its highest was $17.95 in the past 12 months.
What is Travere Therapeutics’s market cap?
Currently, no data Available
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 49 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on May 06, 2024. The company reported -$1.76 earnings per share for the quarter, missing the consensus estimate of -$0.94 by -$0.82.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is -$0.8.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 76,129,020 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -$1.76 in its last earnings report, missing expectations of -$0.94. Following the earnings report the stock price went up 3.053%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Among the largest hedge funds holding Travere Therapeutics’s share is Royce & Associates LLC. It holds Travere Therapeutics’s shares valued at 367K.
---
Travere Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.56 (98.37% Upside)
$14.56 (98.37% Upside)
Blogger Sentiment
Bearish
TVTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.58%
12-Months-Change
Fundamentals
Return on Equity
-303.50%
Trailing 12-Months
Asset Growth
-17.90%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics is focused on developing therapies for rare kidney and metabolic disorders. The biopharmaceutical company's products include FILSPARI (sparsentan), and Thiola and Thiola EC (tiopronin tablets).
---
TVTX Earnings Call
Q1 2024
0:00 / 0:00
---
TVTX Stock 12 Month Forecast
Average Price Target
$14.56
▲(98.37% Upside)
Technical Analysis
Best Analysts Covering TVTX
1 Year
1 Year Success Rate
12/21 ratings generated profit
1 Year Average Return
-0.73%
reiterated a buy rating 6 months ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -0.73% per trade.
---